Associations - Aidixi (disitamab vedotin)

No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1
HER-2 positive	Urothelial Cancer	HER-2 positive	Urothelial Cancer	disitamab vedotin Sensitive: B - Late Trials disitamab vedotin Sensitive : B	disitamab vedotin Sensitive: B - Late Trials disitamab vedotin Sensitive : B
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 overexpression	Urothelial Cancer	HER-2 overexpression	Urothelial Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 expression	Bladder Cancer	HER-2 expression	Bladder Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 overexpression	Gastroesophageal Cancer	HER-2 overexpression	Gastroesophageal Cancer	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	toripalimab-tpzi + disitamab vedotin Sensitive: C3 – Early Trials toripalimab-tpzi + disitamab vedotin Sensitive : C3	toripalimab-tpzi + disitamab vedotin Sensitive: C3 – Early Trials toripalimab-tpzi + disitamab vedotin Sensitive : C3
HER-2 expression	Urothelial Cancer	HER-2 expression	Urothelial Cancer	toripalimab-tpzi + disitamab vedotin Sensitive: C3 – Early Trials toripalimab-tpzi + disitamab vedotin Sensitive : C3	toripalimab-tpzi + disitamab vedotin Sensitive: C3 – Early Trials toripalimab-tpzi + disitamab vedotin Sensitive : C3
HER-2 mutation	Gastric Cancer	HER-2 mutation	Gastric Cancer	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3
HER-2 positive	Bladder Cancer	HER-2 positive	Bladder Cancer	tislelizumab-jsgr + disitamab vedotin Sensitive: C3 – Early Trials tislelizumab-jsgr + disitamab vedotin Sensitive : C3	tislelizumab-jsgr + disitamab vedotin Sensitive: C3 – Early Trials tislelizumab-jsgr + disitamab vedotin Sensitive : C3
HER-2 expression	Salivary Gland Cancer	HER-2 expression	Salivary Gland Cancer	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3
HER-2 underexpression	Gastric Cancer	HER-2 underexpression	Gastric Cancer	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	disitamab vedotin Sensitive: C4 – Case Studies disitamab vedotin Sensitive : C4	disitamab vedotin Sensitive: C4 – Case Studies disitamab vedotin Sensitive : C4
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	disitamab vedotin + zimberelimab Sensitive: C4 – Case Studies disitamab vedotin + zimberelimab Sensitive : C4	disitamab vedotin + zimberelimab Sensitive: C4 – Case Studies disitamab vedotin + zimberelimab Sensitive : C4
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	bevacizumab + disitamab vedotin Sensitive: C4 – Case Studies bevacizumab + disitamab vedotin Sensitive : C4	bevacizumab + disitamab vedotin Sensitive: C4 – Case Studies bevacizumab + disitamab vedotin Sensitive : C4
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D
HER-2 overexpression	Bladder Cancer	HER-2 overexpression	Bladder Cancer	disitamab vedotin Sensitive: D – Preclinical disitamab vedotin Sensitive : D	disitamab vedotin Sensitive: D – Preclinical disitamab vedotin Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	tucatinib + disitamab vedotin Sensitive: D – Preclinical tucatinib + disitamab vedotin Sensitive : D	tucatinib + disitamab vedotin Sensitive: D – Preclinical tucatinib + disitamab vedotin Sensitive : D

Aidixi (disitamab vedotin)

Associations
(27)

Associations
(27)

Aidixi (disitamab vedotin)

Associations(27)

Associations(27)

Associations
(27)

Associations
(27)